Bausch + Lomb Corporation (NYSE:BLCO – Get Free Report) has been assigned an average rating of “Hold” from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $18.75.
Several analysts have weighed in on BLCO shares. Citigroup raised their price target on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Wall Street Zen raised Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. HC Wainwright upped their price objective on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research note on Monday, July 6th. Finally, UBS Group began coverage on shares of Bausch + Lomb in a research report on Thursday, July 30th. They set a “buy” rating and a $21.00 target price for the company.
Check Out Our Latest Stock Report on BLCO
Bausch + Lomb Trading Up 2.4%
Institutional Trading of Bausch + Lomb
A number of hedge funds have recently made changes to their positions in BLCO. Glenview Capital Management LLC raised its position in Bausch + Lomb by 210.8% during the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock valued at $20,216,000 after purchasing an additional 1,053,855 shares in the last quarter. Davidson Kempner Capital Management LP purchased a new position in shares of Bausch + Lomb in the 3rd quarter worth about $14,776,000. Woodline Partners LP boosted its holdings in shares of Bausch + Lomb by 175.3% in the 3rd quarter. Woodline Partners LP now owns 861,053 shares of the company’s stock worth $12,976,000 after purchasing an additional 548,230 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Bausch + Lomb by 428.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after purchasing an additional 242,993 shares during the last quarter. Finally, Whitebox Advisors LLC increased its position in shares of Bausch + Lomb by 15.8% during the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock valued at $17,519,000 after purchasing an additional 150,641 shares during the last quarter. 11.07% of the stock is owned by institutional investors.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
See Also
- Five stocks we like better than Bausch + Lomb
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
